@article {7818,
	title = {Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: A randomized phase II study conducted by the hellenic co-operative oncology group},
	journal = {Oncology},
	volume = {77},
	year = {2009},
	note = {Cited By :6Export Date: 21 February 2017},
	month = {2009},
	pages = {212 - 216},
	abstract = {Objective: A randomized phase II trial was conducted to test whether the addition of gemcitabine to weekly docetaxel could improve the objective response rate and survival outcomes as second-line chemotherapy in patients with metastatic breast cancer who have failed a paclitaxel-containing regimen. Methods: Patients were randomized to receive either weekly docetaxel 40 mg/m2 (group A, n = 34) or the combination of weekly docetaxel 35 mg/m2 with gemcitabine 600 mg/m2 (group B, n = 41). Three consecutive weekly infusions followed by a 1-week rest period represented 1 chemotherapy cycle. Results: The objective response rate was 18\% and 27.5\% in group A and B, respectively (p = 0.413). No statistically significant differences were demonstrated in terms of median overall survival and time to disease progression. The rate and grade 3 and 4 neutropenia were higher in group B (23 vs. 3\%). Conclusions: The weekly administration of docetaxel and gemcitabine did not result in superior clinical outcomes over weekly docetaxel. {\textcopyright} 2009 S. Karger AG, Basel.},
	keywords = {Docetaxel, Gemcitabine, Metastatic breast cancer, Second-line chemotherapy},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-69549087942\&doi=10.1159\%2f000236021\&partnerID=40\&md5=4dab1a442243e2e107d6cbf1d8c04c4d},
	author = {Papadimitriou, C.A. and Kalofonos, H. and Zagouri, F. and Papakostas, P. and Bozas, G. and Makatsoris, T. and Dimopoulos, M.-A. and Fountzilas, G.}
}
